Cuper Martinez, MD

Internal Medicine

Dr. Cuper Martinez is an Internal Medicine Specialist in West Valley City, UT. He graduated with honors from Ponce School of Medicine in 2017. Having more than 4 years of diverse experience, especially in internal medicine, Dr. Cuper Martinez is highly experienced in obesity medicine and hospice and palliative medicine. Dr. Martinez affiliates with Jordan Valley Medical Center, where he serves as Chair of Internal Medicine, and Valeo Home Health and Hospice, where he serves as Medical Director. Dr. Cuper Martinez cooperates with many other physicians and subspecialists in many medical groups such as the U of U, IMC, St. Marks, Steward, etc.

Dr. Cuper Martinez is happily married with a 2- and 4-year-old who makes his life interesting. He loves watching them play soccer and swimming.

Professional Experience:

  • Present Principal Investigator Kalo Clinical Research, Salt Lake City, UT
  • Hospitalist Jordan Valley Medical Center Main and West Campus, West Jordan, UT
  • Provider Hospice and Palliative Medicine Salt Lake City, UT
  • Department of Internal Medicine Chair Jordan Valley Hospital, West Jordan, UT
  • Outpatient Internal Medicine Western Hills, West Valley City, UT
  • Outpatient Internal Medicine Sacred Circle Healthcare West, Valley City, UT

See Education Tab for Research Experience

Medical Degree
Universidad Autónoma de Guadalajara; Guadalajara, Jalisco México - 2010
Hospital De La Concepción Internal Medicine Residency San German, Puerto Rico - 2017
University of Texas in Dallas Premedical/Biology Richardson, Texas - 2012
Board Certified
Internal Medicine


2965 W. 3500 S.
West Valley City, UT 84119


Research Experience:

  • Principal Investigator, SELECT – Semaglutide effects on cardiovascular outcomes in people overweight or with obesity.
  • Principal Investigator, A 12-week randomized controlled trial to compare TOUJEO® and TRESIBA® in terms of glucose
    values in target range and variability during continuous glucose monitoring in patients with type 1 diabetes mellitus.
  • Sub Investigator, Protocol I8F-MC-GPGN The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular
    Events in Patients with Type 2 Diabetes (SURPASS-CVOT).
  • Sub Investigator, A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 Week Variable
    Length Study to Assess the Efficacy and Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose
    Inhaler (MDI) Relative to Budesonide and Formoterol Fumarate MDI and Symbicort® Pressurized MDI in Adult and
    Adolescent Participants with Inadequately Controlled Asthma (KALOS).
  • Sub-Investigator, Treatment Use Study of Patients Safety Following Transfusion of Intercept Platelet Components
    Principal Investigator, A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of
    IONIS-AGT-LRX, an Antisense Inhibitor of Angiotensinogen Production Administered Subcutaneously for 12 Weeks to
    Hypertensive Patients with Uncontrolled Blood Pressure.
  • Sub Investigator, Protocol Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy,
    Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis
    Bronchiectasis – The ASPEN Stud.